Johnson & Johnson and Legend Biotech have officially withdrawn their abstract intended for presentation at the upcoming American Society of Hematology (ASH) annual meeting, which evaluated Carvykti in comparison to competing CAR-T therapies developed by Gilead and Arcellx. This decision was confirmed by Alan Bash, president of Legend’s Carvykti division, who stated that the withdrawal was made in alignment with the authors and expressed optimism about future opportunities to present the data.
The withdrawal comes at a critical time as the CAR-T therapy market becomes increasingly competitive, with multiple players vying for dominance. The implications of this decision could affect investor sentiment and market positioning for both companies, particularly as they navigate the complexities of regulatory approval and market access. Stakeholders in the pharma B2B sector, especially those involved in regulatory affairs and clinical development, will be closely monitoring how this situation unfolds and what it may mean for future data disclosures.
Start your 7-day trial and see what the database can do →
